BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the ...

Targeted Therapy Delivered Forward-looking statements advisory This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forw ...

Summary of Lisada Therapeutics Conference Call Company Overview - **Company Name**: Lisada Therapeutics (NasdaqCM:LSTA) - **Industry**: Clinical stage pharmaceutical company focused on solid tumor cancer treatment - **Management Team**: Over 200 years of combined experience in drug development across big pharma and emerging companies [2][3] Core Points and Arguments - **Market Need**: Over 90% of newly diagnosed cancers are solid tumors, with a growing prevalence, particularly pancreatic cancer, which is projected to become the second leading cause of cancer death in the U.S. by the end of the decade [4] - **Product Development**: The company is developing **Sotepatide**, a proprietary cyclic peptide designed to penetrate tumor stroma and reduce immunosuppressive environments, enhancing the efficacy of various anticancer therapies [5][6] - **Intellectual Property**: Strong IP portfolio protecting products until 2040, with several strategic alliances and licenses established [3][9][8] - **Clinical Trials**: - Completed Phase 2B and is Phase 3 ready for metastatic pancreatic ductal adenocarcinoma (MPDAC) [12] - Significant improvement in overall survival by 5-6 months compared to standard care, representing a 150% improvement [14] - Cohort A and B data from trials show promising results in overall survival and progression-free survival (PFS) [18][20] - Positive preliminary data from the I LISTA study combining Sotepatide with chemotherapy and immunotherapy [23] Financial Position - **Cash Reserves**: Approximately $20 million available, with a cash runway extending into early 2027 [30] - **Debt-Free**: The company maintains a clean capital structure [30] Regulatory Status - **Designations**: Fast track designation in the U.S. for pancreatic cancer, orphan designations in both the U.S. and Europe, and rare pediatric disease designation for osteosarcoma [27] - **Phase 3 Protocol**: Approved by the FDA, with ongoing discussions with the EMA for global registration [28] Additional Insights - **Combination Therapy**: Sotepatide can be used with various anticancer modalities, showing improved efficacy without increasing safety risks [21][22] - **Future Studies**: Ongoing studies in other cancers, including cholangiocarcinoma and gastroesophageal adenocarcinoma, with data expected in the near future [29] - **Market Strategy**: Plans to raise capital for further development and potential licensing agreements to enhance product offerings [27] Conclusion Lisada Therapeutics is positioned strongly within the oncology market, with innovative therapies addressing significant unmet medical needs, a solid financial foundation, and a robust pipeline of clinical data supporting its product efficacy and safety. The company is actively pursuing strategic partnerships to enhance its market presence and therapeutic offerings [31]

Group 1 - Lisata Therapeutics will present a corporate overview at the LD Micro Main Event XIX Conference in San Diego from October 19-21, 2025 [1][3] - The presentation is scheduled for October 20th at 10:30 a.m. Pacific time, with opportunities for one-on-one meetings throughout the conference [2] - The LD Micro Main Event XIX will feature around 120 companies presenting and conducting private meetings with investors [3] Group 2 - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its lead product candidate, certepetide, designed to enhance the targeting of anti-cancer drugs [4] - The company has established significant commercial and R&D partnerships based on its CendR Platform® technology and anticipates announcing multiple milestones over the next 1.5 years [4] - Lisata expects its projected capital to fund operations through the fourth quarter of 2026, including anticipated data milestones from ongoing and planned clinical trials [4]

Core Insights - Lisata Therapeutics Inc has entered a collaboration with Catalent to leverage its lead molecule, certepetide, across various cancer types and treatment modalities [1] Revenue Potential - The Catalent deal is described as having "unlimited revenue potential," particularly in the rapidly growing antibody-drug conjugate (ADC) class in oncology [2] - Major players in the industry are actively developing ADCs and seeking ways to enhance their efficacy [2] Partnership Details - The arrangement with Catalent is non-exclusive, allowing Lisata to partner with other companies in the ADC space [3] - This partnership introduces a new therapeutic modality, as certepetide has not been tested specifically with ADCs prior to this collaboration [4] Validation of Technology - The collaboration marks the first instance of a third party using a certepetide-related molecule conjugated to another molecule, validating the hypothesis of co-administration or conjugation benefits [5] Strategic Vision - The strategic vision for certepetide is to exploit its broad applicability across various cancers and treatment modalities, primarily through partnerships [6] - Collaborating with a well-established company like Catalent is seen as a significant advancement for Lisata, which recognizes its limitations as a small company [7] Future Partnerships - Lisata is actively seeking additional partnerships to further exploit the applicability of certepetide and is open to evaluating different transaction types [8]

Group 1 - Lisata Therapeutics has initiated a global product license agreement with Catalent, allowing Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) using its SMARTag technology platform [1][2] - The partnership is seen as a validation of certepetide's versatility and positions Lisata's technology within a leading ADC platform [1] - Catalent has acquired non-exclusive rights to develop and commercialize products utilizing certepetide and its analogs, highlighting the broad potential of certepetide [2]

Core Insights - Catalent has secured global rights to evaluate certepetide and its analogs for use as SMARTag payloads in antibody-drug conjugates (ADCs) targeting difficult-to-treat diseases [1][2] - The collaboration is based on positive preclinical results indicating the potential of certepetide to enhance tumor targeting and treatment outcomes [3][4] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors and serious diseases, with its lead product candidate being certepetide [5][6] - Catalent, a leading global contract development and manufacturing organization, aims to develop and supply products that improve patient health [8] Licensing Agreement Details - Under the licensing agreement, Catalent gains worldwide, non-exclusive rights to develop and commercialize bioconjugate products containing certepetide, including partnerships with third parties [2] - Lisata is eligible for over $10 million in tiered milestone payments and revenue sharing from future sales and partnerships [2] Preclinical Study Insights - Preclinical studies have shown that incorporating iRGD peptides into ADCs may improve efficacy and pharmacokinetics, suggesting a novel payload class [4] - The collaboration will be highlighted at the upcoming World ADC conference in San Diego [3] Certepetide Mechanism and Designation - Certepetide is designed to activate a novel uptake pathway for anti-cancer drugs, enhancing their ability to target and penetrate solid tumors [6][7] - Certepetide has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers [7]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - Lisata Therapeutics announced promising preliminary data from the Phase 1/2a CENDIFOX trial for its investigational drug certepetide, aimed at treating pancreatic ductal adenocarcinoma (PDAC) [1][3][4] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [7] - The company is exploring the potential of certepetide to enhance the effectiveness of various treatment modalities for solid tumors [6] Trial Details - The CENDIFOX trial is evaluating certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers [1][2] - The trial is led by Dr. Anup Kasi at The University of Kansas Cancer Center [1][8] Preliminary Data Highlights - Among 35 patients in the PDAC cohort, 10 completed pre-surgical therapy and were eligible for resection, achieving a 50% R0 resection rate and a 70% pathologic partial response rate [3][4] - The trial reported a 60% two-year overall survival rate and a 12-month median disease-free survival [3][4] - Enhanced immune cell infiltration and increased expression of immune markers were observed, indicating a potential shift from "immune-cold" to "immune-hot" tumors [3][4] Significance of Findings - The results suggest that certepetide may improve drug delivery and modulate the tumor microenvironment, offering a new treatment approach for pancreatic cancer [3][4] - The findings are particularly significant given the poor prognosis associated with pancreatic cancer, which has a five-year survival rate of only 13% [4]

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's investigational drug, certepetide, is designed to enhance the targeting and penetration of anti-cancer drugs into solid tumors through a novel uptake pathway [3] Upcoming Presentation - David J. Mazzo, Ph.D., President and CEO of Lisata, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1] - The on-demand recording of Dr. Mazzo's presentation will be available starting September 5, 2025, at 7:00 a.m. Eastern Time [2] Future Expectations - Lisata anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into the fourth quarter of 2026 [3] - The company has established significant commercial and R&D partnerships based on its CendR Platform technology [3]